$Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.$

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

OBJECTIVE: To evaluate predictors of vertebral fractures, including a threshold for bone mineral density (BMD), in patients receiving oral glucocorticoids (GCs). METHODS: Data were obtained from 2 randomized clinical trials (prevention and treatment trials of risedronate) using similar methods, but...

Full description

Bibliographic Details
Main Authors:	Van Staa, T, Laan, R, Barton, I, Cohen, S, Reid, D, Cooper, C
Format:	Journal article
Language:	English
Published:	2003

Similar Items

PREDICTORS FOR VERTEBRAL FRACTURES AND FRACTURE THRESHOLD IN PATIENTS USING ORAL GLUCOCORTICOIDS
by: van Staa, T, et al.
Published: (2003)

The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids.
by: van Staa, T, et al.
Published: (2003)

The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids.
by: van Staal, T, et al.
Published: (2003)

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate
by: Watts, N, et al.
Published: (2004)

CUMULATIVE RISKS OF FRACTURE IN PATIENTS USING ORAL GLUCOCORTICOIDS
by: Van Staa, T, et al.
Published: (2004)

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
by: Watts, N, et al.
Published: (2004)

Fracture risk with intermittent high-dose oral glucocorticoid therapy.
by: De Vries, F, et al.
Published: (2007)

Bone loss and inhaled glucocorticoids.
by: van Staa, T, et al.
Published: (2002)

Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.
by: van Staa, T, et al.
Published: (2007)

Risk of incident fracture is associated with dose, duration and recency of oral glucocorticoid exposure
by: Robinson, DE, et al.
Published: (2018)

The relationship between bone density and incident vertebral fracture in men and women.
by: O'Neill, T
Published: (2002)

Low grip strength is associated with bone mineral density and vertebral fracture in women.
by: Dixon, W, et al.
Published: (2005)

A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids.
by: van Staa, T, et al.
Published: (2005)

The associations between QCT-based vertebral bone measurements and prevalent vertebral fractures depend on the spinal locations of both bone measurement and fracture
by: Demissie, S., et al.
Published: (2016)

Use of cyclical etidronate and prevention of non-vertebral fractures.
by: van Staa, T, et al.
Published: (1998)

Risk of Fracture and Bone Mineral Density in Stroke Response
by: Pouwels, S, et al.
Published: (2010)

The limitations of using simple definitions of glucocorticoid exposure on the prediction of fracture risk
by: Robinson, D, et al.
Published: (2018)

Are risk factors for vertebral deformities associated with reduced bone density? The EVOS study
by: Masaryk, P, et al.
Published: (1996)

Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.
by: de Vries, F, et al.
Published: (2007)

Prior clinical vertebral fractures are a particularly strong predictor of hip fracture: A meta-analysis
by: Johnell, O, et al.
Published: (2006)

Bone remodelling does not decline after menopause in vertebral fracture osteoporosis.
by: Wand, J, et al.
Published: (1992)

Re: Use of cyclic etidronate and the prevention of non-vertebral fractures - Reply
by: van Staa, T, et al.
Published: (1998)

The importance of vertebral fracture
by: Reeve, J, et al.
Published: (2003)

Vertebral fractures predict subsequent fractures.
by: Melton, L, et al.
Published: (1999)

Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy.
by: Varonos, S, et al.
Published: (1987)

The localisation of glucocorticoid receptors in human bone
by: Abu, E, et al.
Published: (1997)

Risk of new vertebral fracture in the year following a fracture.
by: Lindsay, R, et al.
Published: (2001)

Missing an osteoporotic vertebral fracture
by: Cheong, A.T., et al.
Published: (2009)

Missing an osteoporotic vertebral fracture.
by: Cheong, Ai Theng, et al.
Published: (2009)

The limitations of using simple definitions of glucocorticoid exposure to predict fracture risk: a cohort study
by: Robinson, D, et al.
Published: (2018)

Use of oral corticosteroids and risk of fractures.
by: Van Staa, T, et al.
Published: (2000)

CHARACTERISTICS OF PREVALENT VERTEBRAL DEFORMITY AND THE RISK OF INCIDENT VERTEBRAL FRACTURE
by: Lunt, M, et al.
Published: (2002)

Children and the risk of fractures caused by oral corticosteroids.
by: van Staa, T, et al.
Published: (2003)

VERTEBRAL FRACTURE RISK REDUCTION IS INDEPENDENT OF THE MAGNITUDE OF BMD CHANGE
by: Adachi, J, et al.
Published: (2004)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study.
by: Lunt, M, et al.
Published: (2001)

VARIATIONS IN VERTEBRAL DEFORMITY PREVALENCE IN EUROPE ARE STATISTICALLY DEPENDENT ON POPULATION DIFFERENCES IN BONE-DENSITY - THE EVOS-STUDY
by: Reeve, J, et al.
Published: (1995)

Population-based geographic variations in DXA bone density in Europe: the EVOS Study. European Vertebral Osteoporosis.
by: Lunt, M, et al.
Published: (1997)

Peripheral and axial measurements of trabecular bone density in patients suspected of idiopathic vertebral osteoporosis.
by: Bydder, G, et al.
Published: (1983)

Use of beta-blockers and risk of hip and vertebral fracture: relationships to daily and cumulative dose
by: De Vries, F, et al.
Published: (2006)